BACKGROUND: Clinical symptoms of Dengue vary from mild febrile illness to severe infection. A potent pro-inflammatory cytokine, IL-17, secreted by mainly Th17 cells mediate inflammation and autoimmune diseases. Role of IL-17 in pathogenesis of dengue virus (DV) infection is not clear. METHODS: Total 211 dengue patients and 70 healthy controls were enrolled. IL-17 level was tested in serum samples from all cases and controls. Cases were grouped as either dengue or severe dengue; based on WHO (2009) classification. Anti DV IgG antibody detection and DV serotype specific PCR were also done. Levels of IL-17 in dengue and severe dengue patients, primary and secondary DV infection were compared. Association of DV serotypes with severity of illness and various clinical and laboratory features with IL-17 levels were analyzed. RESULTS: Of total 211cases, 90 and 121cases were presenting as dengue and severe dengue illness, respectively. Levels of IL-17 were significantly higher in dengue patients as compared to control. Mean level of IL-17 was higher in severe cases than non severe cases; however difference was not statistically significant. Stratified analysis of IL-17 level in different age group showed significantly high IL-17 levels in children with severe dengue. Mean level of IL-17 was also significantly higher in cases with secondary DV infection in comparison to primary DV infection. Levels of IL-17 were higher in patients with DV-2 infection in comparison to cases with DV-1 and DV-3 infection. Significant positive association of high IL-17 levels was seen with pleural effusion and respiratory distress. CONCLUSION: IL-17 appears to be associated with severe DV infection. It is very important to understand the exact role of IL-17 in the pathogenesis of severe DV infection.
BACKGROUND: Clinical symptoms of Dengue vary from mild febrile illness to severe infection. A potent pro-inflammatory cytokine, IL-17, secreted by mainly Th17 cells mediate inflammation and autoimmune diseases. Role of IL-17 in pathogenesis of dengue virus (DV) infection is not clear. METHODS: Total 211 dengue patients and 70 healthy controls were enrolled. IL-17 level was tested in serum samples from all cases and controls. Cases were grouped as either dengue or severe dengue; based on WHO (2009) classification. Anti DV IgG antibody detection and DV serotype specific PCR were also done. Levels of IL-17 in dengue and severe dengue patients, primary and secondary DV infection were compared. Association of DV serotypes with severity of illness and various clinical and laboratory features with IL-17 levels were analyzed. RESULTS: Of total 211cases, 90 and 121cases were presenting as dengue and severe dengue illness, respectively. Levels of IL-17 were significantly higher in dengue patients as compared to control. Mean level of IL-17 was higher in severe cases than non severe cases; however difference was not statistically significant. Stratified analysis of IL-17 level in different age group showed significantly high IL-17 levels in children with severe dengue. Mean level of IL-17 was also significantly higher in cases with secondary DV infection in comparison to primary DV infection. Levels of IL-17 were higher in patients with DV-2 infection in comparison to cases with DV-1 and DV-3 infection. Significant positive association of high IL-17 levels was seen with pleural effusion and respiratory distress. CONCLUSION: IL-17 appears to be associated with severe DV infection. It is very important to understand the exact role of IL-17 in the pathogenesis of severe DV infection.
Authors: Aileen G Rowan; Jean M Fletcher; Elizabeth J Ryan; Barry Moran; John E Hegarty; Cliona O'Farrelly; Kingston H G Mills Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422
Authors: Sumanta Mukherjee; Dennis M Lindell; Aaron A Berlin; Susan B Morris; Thomas P Shanley; Marc B Hershenson; Nicholas W Lukacs Journal: Am J Pathol Date: 2011-05-03 Impact factor: 4.307
Authors: M M B Moreno-Altamirano; M Romano; M Legorreta-Herrera; F J Sánchez-García; M J Colston Journal: Scand J Immunol Date: 2004-12 Impact factor: 3.487
Authors: Juliet A Emamaullee; Joy Davis; Shaheed Merani; Christian Toso; John F Elliott; Aducio Thiesen; A M James Shapiro Journal: Diabetes Date: 2009-03-16 Impact factor: 9.461
Authors: Marcos Luiz Gaia Carvalho; Luiz Fábio Magno Falcão; Jeferson da Costa Lopes; Caio Cesar Henriques Mendes; Fábio Alves Olímpio; Vanessa do Socorro Cabral Miranda; Lais Carneiro Dos Santos; Daniel Dias Pinheiro de Moraes; Marcos Virgilio Bertonsin Filho; Luccas Delgado da Costa; Raimunda do Socorro da Silva Azevedo; Ana Cecília Ribeiro Cruz; Vanessa Costa Alves Galúcio; Lívia Caricio Martins; Maria Irma Seixas Duarte; Arnaldo Jorge Martins Filho; Jorge Rodrigues de Sousa; Pedro Fernando da Costa Vasconcelos; Juarez Antônio Simões Quaresma Journal: Cells Date: 2022-06-28 Impact factor: 7.666
Authors: A Kamaladasa; N Wickramasinghe; T N Adikari; L Gomes; N L A Shyamali; M Salio; V Cerundolo; G S Ogg; G Neelika Malavige Journal: Clin Exp Immunol Date: 2016-08 Impact factor: 4.330
Authors: Adeline S L Yeo; Nur Atiqah Azhar; Wanyi Yeow; C Conover Talbot; Mohammad Asif Khan; Esaki M Shankar; Anusyah Rathakrishnan; Azliyati Azizan; Seok Mui Wang; Siew Kim Lee; Mun Yik Fong; Rishya Manikam; Shamala Devi Sekaran Journal: PLoS One Date: 2014-04-11 Impact factor: 3.240